# Verastem Inc. (VSTM) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.77, market value $1.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Verastem Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 38.4×**. Each dollar of revenue is priced at 38.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 17.7×**. The shares trade at 17.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Operating margin: -550.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -677.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -366.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 125.5%**. Return on all capital, debt included, is 125.5%: comfortably above what that capital costs.
- **Return on assets: -85.0%**. Each dollar of assets produces -85.0% of profit.

## Growth
- **Revenue growth (1 yr): 209.1%** (3-yr 128.4%/yr, 5-yr -19.0%/yr). Revenue grew 209.1% over the last year, against -19.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 17.5%**. Earnings per share rose 17.5%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.71**. Debt is 0.71 times equity, moderate leverage.
- **Net debt / EBITDA: 1.0×**. It would take 1.0 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: -149.5×**. Operating profit covers interest only -149.5×: fragile.
- **Current ratio: 3.09** (quick 3.09). Current assets cover the next year's liabilities 3.09 times.
- **Altman Z-score: 2.67**. A Z-score of 2.67 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Verastem Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Verastem Inc.; the consensus is strong_buy, with an average price target of $17.11 (+75% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 1.5%** (YTD 24.2%, 3-mo 68.5%). The shares are up 1.5% over twelve months including dividends.
- **From 52-week high: -9.7%** (184.8% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 1.14** (volatility 76%). Beta of 1.14 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=VSTM · Page: https://foliofundamentals.com/stocks/vstm

Not investment advice.